Hansa Biopharma AB Long-term Investment Intensity
Hansa Biopharma AB long-term investment intensity. Hansa Biopharma AB (HNSA) has a Long-term Investment Intensity of 9.1% as of March 2019. Long-term investments of Skr81.97 Million represent 9.1% of total assets of Skr898.03 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Read total liabilities of Hansa Biopharma AB for a breakdown of total debt and financial obligations.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Long-term Investment Intensity of Hansa Biopharma AB (2015–2018)
Long-term investment intensity of Hansa Biopharma AB from 2015 to 2018. This chart shows how Hansa Biopharma AB's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of March 2019, the intensity stands at 9.1%, reflecting long-term investments of Skr81.97 Million against total assets of Skr898.03 Million SEK.
Hansa Biopharma AB Long-term Investment Intensity by Year (2015–2018)
Hansa Biopharma AB long-term investment intensity by year from 2015 to 2018. The table below presents the year-by-year Long-term Investment Intensity for Hansa Biopharma AB from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see HNSA total assets.
| Year | LT Investment Intensity | LT Investments (SEK) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2018 | 4.2% | Skr39.53 Million | Skr944.82 Million | ▲ +1.5 pp |
| 2017 | 2.7% | Skr18.51 Million | Skr680.41 Million | ▼ -2.0 pp |
| 2016 | 4.7% | Skr14.57 Million | Skr310.67 Million | ▲ +1.4 pp |
| 2015 | 3.3% | Skr7.28 Million | Skr224.09 Million | — |